转移性肾细胞癌一线免疫肿瘤联合治疗:IMDC数据库结果
基于IMDC数据库的回顾性研究,比较转移性肾细胞癌一线IOVE联合方案与ipi-nivo的疗效。结果显示两组一线缓解率、至治疗失败时间、至下次治疗时间和总生存均无显著差异。多数患者二线接受VEGF为基础的治疗,其中初始ipi-nivo组二线缓解率更高。
要点
- IOVE与ipi-nivo一线疗效无显著差异
- 二线多采用VEGF为基础治疗
- 初始ipi-nivo者二线缓解率更高
核心结论
- IOVE联合方案与ipi-nivo在转移性肾细胞癌一线治疗中的疗效无显著差异。
- 多数患者二线接受VEGF为基础治疗,初始ipi-nivo者二线缓解率更高。
研究设计与样本
- 回顾性队列研究,使用IMDC数据集,纳入113例接受IOVE联合方案和75例接受ipi-nivo的患者。
主要发现
- 一线缓解率IOVE组33% vs ipi-nivo组40%,组间差异7%(95%CI -8%至22%,p=0.4)。
- 中位至治疗失败时间14.3 vs 10.2个月(p=0.2),至下次治疗时间19.7 vs 17.9个月(p=0.4)。
- 中位总生存未成熟但无统计学差异(p=0.17);调整后风险比分别为TTF 0.71(95%CI 0.46-1.12,p=0.14)、TNT 0.65(95%CI 0.38-1.11,p=0.11)、OS 1.74(95%CI 0.82-3.68,p=0.14)。
- 二线至治疗失败时间无显著差异(3.7 vs 5.4个月;p=0.4;n=55)。
临床怎么用
- 一线IOVE联合方案与ipi-nivo均可作为转移性肾细胞癌的治疗选择,疗效相似。
- 二线治疗多采用VEGF为基础方案,初始ipi-nivo者可能对后续VEGF治疗缓解率更高。
局限性
- 回顾性研究设计。
- 样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In metastatic renal-cell carcinoma (mRCC), recent data have shown efficacy of first-line ipilimumab and nivolumab (ipi-nivo) as well as immuno-oncology (IO)/vascular endothelial growth factor (VEGF) inhibitor combinations. Comparative data between these strategies are limited. OBJECTIVE: To compare the efficacy of ipi-nivo versus IO-VEGF (IOVE) combinations in mRCC, and describe practice patterns and effectiveness of second-line therapies. DESIGN, SETTING, AND PARTICIPANTS: Using the International Metastatic Renal-cell Carcinoma Database Consortium (IMDC) dataset, patients treated with any first-line IOVE combination were compared with those treated with ipi-nivo. INTERVENTION: All patients received first-line IO combination therapies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: First- and second-line response rates, time to treatment failure (TTF), time to next treatment (TNT), and overall survival (OS) were analysed. Hazard ratios were adjusted for IMDC risk factors. RESULTS AND LIMITATIONS: In total, 113 patients received IOVE combinations and 75 received ipi-nivo. For IOVE combinations versus ipi-nivo, first-line response rates were 33% versus 40% (between-group difference 7%, 95% confidence interval [CI] -8% to 22%, p = 0.4), TTF was 14.3 versus 10.2 mo (p = 0.2), TNT was 19.7 versus 17.9 mo (p = 0.4), and median OS was immature but not statistically different (p = 0.17). Adjusted hazard ratios for TTF, TNT, and OS were 0.71 (95% CI 0.46-1.12, p = 0.14), 0.65 (95% CI 0.38-1.11, p = 0.11), and 1.74 (95% CI 0.82-3.68, p = 0.14), respectively. Sixty-four (34%) patients received second-line treatment. In patients receiving subsequent VEGF-based therapy, second-line response rates were lower in the IOVE cohort than in the ipi-nivo cohort (15% vs 45%; between-group difference 30%, 95% CI 3-57%, p = 0.04; n = 40), though second-line TTF was not significantly different (3.7 vs 5.4 mo; p = 0.4; n = 55). Limitations include the study's retrospective design and sample size. CONCLUSIONS: There were no significant differences in first-line outcomes between IOVE combinations and ipi-nivo. Most patients received VEGF-based therapy in the second line. In this group, second-line response rate was greater in patients who received ipi-nivo initially. PATIENT SUMMARY: There were no significant differences in key first-line outcomes for patients with metastatic renal-cell carcinoma receiving immuno-oncology/vascular endothelial growth factor inhibitor combinations versus ipilimumab and nivolumab.
引用
- Dudani S, Graham J, Wells JC, et al. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019. PMID: 31445844. doi:10.1016/j.eururo.2019.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。